All In Biotech

Drug Trial Radar · NCT01694966

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Last checked: Nov 20, 2026Latest source record: Nov 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,249 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,249

Actual

Start

Sep 2013

Primary completion

Oct 2016

Study completion Oct 2016

Sponsor

Lead sponsor
Cosmo Technologies LtdIndustry
Sponsor type
Industry
First posted
Sep 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Screening
Who can join
All sexes, from 50 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.

Conditions

  • Colorectal Cancer

Interventions

  • Methylene Blue MMX®Drug

  • PlaceboDrug

    Sugar pill manufactured to mimic Methylene Blue MMX® tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To Assess the Detection Efficacy of Chromoendoscopy Performed With 200mg Methylene Blue MMX® 25 mg Tablets Versus Placebo Tablets (White Light Endoscopy) in Terms of the Proportion of Subjects With at Least One Histologically Proven Adenoma or Carcinoma.Time frame: +7 days

Locations

19 sites in 8 countries. Site status is shown where the registry gives one.

  • Dr Michelle Young

    Phoenix, Arizona

  • Dr Francesco Ramirez

    Scottsdale, Arizona

  • Dr David Gatof

    Lafayette, Colorado

  • Dr Michael Wallace

    Jacksonville, Florida

  • Dr Prateek Sharma

    Kansas City, Kansas

  • Dr Marcia Canto

    Baltimore, Maryland

  • Dr David Bruining

    Rochester, Minnesota

  • Dr Raf Bisschop

    Leuven, Belgium

  • Dr Norman Marcon

    Toronto, Ontario, Canada

  • Dr Ralf Kiesslich

    Wiesbaden, Germany

  • Dr Renato Cannizzaro

    Aviano, Italy

  • Dr Cesare Hassan

    Rome, Italy

  • Dr Alessandro Repici

    Rozzano, Italy

  • Dr Limas Kupcinskas

    Kaunas, Lithuania

  • Dr Evelien Dekker

    Amsterdam, Netherlands

  • Dr Manoon Spander

    Rotterdam, Netherlands

  • Dr Peter Siersema

    Utrecht, Netherlands

  • Dr James East

    Oxford, United Kingdom

  • Dr Matthew Rutter

    Stockton-on-Tees, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.